Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, if he will make it his policy to conduct a lessons learned review following the negotiations with AstraZeneca for investment in Speke.

AstraZeneca’s decision not to invest in Speke is deeply disappointing. The Government regularly reviews it’s grant process and routinely seeks applicant feedback. The Government also continues to engage positively with AstraZeneca, including on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. Support includes the Life Sciences Innovative Manufacturing Fund, which will allocate up to £520 million to deliver economic growth and build health resilience.